Faulty FreeStyle Libre 3 Sensors; Endocrine Society Merger; More Levemir Pushback

FHS
July 31, 2024
3:01 am

Abbott issued an urgent alert about faulty sensors on a few lots of FreeStyle Libre 3 continuous glucose monitors.

Researchers found no link between DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists and the development of diabetic macular edema. (Journal of Diabetes and Its Complications)

The Endocrine Society said it is merging with the Association of Program Directors in Endocrinology, Diabetes, and Metabolism.

In the wake of Novo Nordisk’s plan to pull its long-acting insulin (Levemir) from the market by the end of 2024, some patients have described events of hypoglycemia and rapid glucose fluctuations with other long-acting insulins Novo recommended as safe alternatives. (Reuters)

A work group issued clinical guidance for perioperative care of transgender and gender-diverse individuals. (Anaesthesia)

Fractyl Health announced that the FDA granted a breakthrough device designation for its Revita System for weight-loss maintenance after discontinuation of a GLP-1 receptor agonist. An outpatient endoscopic procedure, Revita works by resurfacing the mucosal lining of the duodenum.

Following positive results from the phase II VENTURE study, Viking Therapeutics said it plans to move its investigational subcutaneous GLP-1/GIP obesity drug into a phase III trial.

When ChatGPT was asked to generate nutritional management plans for type 2 diabetes and metabolic syndrome, dietitians identified a number of gaps in the output generated. (European Journal of Clinical Nutrition)

About 14% of all U.S. conventional pesticide active ingredients are per- and polyfluoroalkyl substances, a class of endocrine-disrupting chemicals. (Environmental Health Perspectives)

Higher levels of phenylacetylglutamine — a gut-microbiota-related metabolite — were linked with elevated coronary heart disease risk, especially among women who ate more animal foods and fewer plant-based foods. (Journal of Clinical Endocrinology & Metabolism)

In a 12-month phase II study, beta-cell function was 49% higher in adolescents with recent-onset type 1 diabetes treated with the monoclonal antibody ustekinumab (Stelara) versus placebo. (Nature Medicine)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Be Bio raises $82M to fund work on B cell therapy in hemophilia B

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 23, 2024

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab

September 13, 2024

Mediterranean Diet After Afib Ablation: Maybe?

BOSTON — An olive oil-enhanced Mediterranean diet didn’t help prevent atrial fibrillation (Afib, or AF) recurrence after ablation in the PREDIMAR randomized trial, although there

May 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.